Stridebio Inc. landed a collaboration and license agreement with Takeda Pharmaceutical Co. Ltd. to develop in vivo adeno-associated virus- (AAV) based therapies for three targets, including Friedreich's ataxia (FA). Stridebio is eligible to receive about $680 million in future development and commercial milestones from Takeda, plus royalties on global net sales of commercial products the collaboration produces.
Springworks Therapeutics Inc. has closed a $125 million series B preferred stock financing, energizing its two late-stage rare disease oncology programs, nirogacestat (PF-03084014), a gamma-secretase inhibitor for treating desmoid tumors, and PD-0325901, an MEK inhibitor for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas.
Gilead Sciences Inc. and Galapagos NV announced week 24 results for phase III studies Finch 1 and 3 of filgotinib in rheumatoid arthritis (RA), saying both studies reached their primary endpoints and that Finch 1 hit key secondary endpoints.
Stridebio Inc. landed a collaboration and license agreement with Takeda Pharmaceutical Co. Ltd. to develop in vivo adeno-associated virus- (AAV) based therapies for three targets, including Friedreich's ataxia (FA). Stridebio is eligible to receive about $680 million in future development and commercial milestones from Takeda, plus royalties on global net sales of commercial products the collaboration produces.
Eli Lilly and Co.'s new partnering deal with privately-held Immunext Inc. to research and globally license an antibody to treat certain autoimmune diseases is another sign that Lilly is deepening its commitment to the immunology space.
Sana Biotechnology Inc., which launched in January, has struck a license agreement with Harvard University's Office of Technology Development to produce hypoimmunogenic stem cells that can be transplanted into patients and not trigger immune rejection. Sana, a regenerative medicine company founded by former Juno Therapeutics Inc. execs Hans Bishop and Steve Harr, focuses on creating engineered cells as medicine for patients.
Spruce Biosciences' tildacerfont (SPR-001) for congenital adrenal hyperplasia (CAH), a rare endocrine disorder, passed muster in a phase II experiment. Proof-of-concept data were disclosed at the Endocrine Society's annual meeting in New Orleans, ENDO 2019, for the oral corticotrophin-releasing factor type 1 receptor agonist.
Sorrento Therapeutics Inc.'s majority owned subsidiary Scilex Pharmaceuticals Inc. will merge with Semnur Pharmaceuticals, creating a new company, Scilex Holding Co., focusing on non-opioid pain management. Scilex's lead product is Ztlido, a lidocaine topical system, and Semnur's lead compound is a non-opioid corticosteroid gel that's in phase III pivotal studies. Sorrento said the merger positions Scilex Holding to become "a global leader in non-opioid pain management."
Imago Biosciences Inc. has received a boost in the form of $40 million series B financing led by Omega Funds. "These funds will support two phase IIb studies in two myeloproliferative diseases and several investigator-initiated studies in related diseases," Hugh Rienhoff Jr., Imago's CEO told BioWorld. Other investors in the financing include Frazier Healthcare Partners, Amgen Ventures, MRL Ventures Fund, Highlight Capital, Pharmaron and Greenspring Associates.
Pfizer Inc. joins several big pharma companies, including Roche Holding AG and Novartis AG, who have recently cut gene therapy deals, with its acquisition of a 15 percent equity interest in privately held Vivet Therapeutics SAS.
